SIGNANT HEALTH
THE EVIDENCE GENERATION COMPANY™

SmartSignals™ Solutions for GVHD



DEVELOPING BETTER GVHD TREATMENTS STARTS WITH BETTER ENDPOINT QUALITY

The medical research community has made significant strides in understanding the pathophysiology driving graft versus host disease (GVHD), but work remains in terms of discovering effective treatment options. Leverage Signant's SmartSignals™ **end-to-end solutions** as well as our **in-house expertise** in rare disorders to address research challenges.

CAPTURE BETTER PRO DATA

Most GVHD protocols include several site- or home-based patient-reported outcome measures such as the Lee GVHD Symptom Scale. Signant's SmartSignals eCOA platform digitalizes the PRO experience to improve data quality and reduce patient burdens. Built-in prompts and engagement features ensure assessments are completed on-time and with fewer errors than pen and paper capture methods.

CONDUCT STUDY ACTIVITIES REMOTELY

Reach participants where they are by offering solutions that facilitate remote study activities. Signant's comprehensive range of solutions, global project teams, and international regulatory know-how will help you conduct trial activities anywhere and any way. Our clinical science team provides guidance and oversight to optimize remote study operations.

INCREASE OPERATIONAL EFFICIENCY

Take control of inventory management complexities and simplify randomization for multi-arm trial designs with Signant's global RTSM solution. Study teams trust our solution to not only launch studies faster but to handle patient cohorts, study supply forecasting, and data transfers with efficiency and accuracy.

MAKE IT EASIER TO PARTICIPATE

Simplify the clinical trial experience for patients and sites alike by providing tools like eConsent and Telemedicine. These solutions help reduce unnecessary site visits, improve remote collaboration between sites and patients, and ensure protocol adherence.

WORK WITH GVHD EXPERTS

From consulting on outcome measure selection and implementation to reducing burdens on sites and patients, Signant's in-house experts will help you navigate common GVHD challenges throughout the study lifecycle. Talk through your protocol with our rare disease experts experienced in GVHD studies.

DIGITALIZE THE PROCESS

Each solution and service within our SmartSignals evidence generation platform can be applied to a study independently. However, when combined, they create an intuitive and powerful digital ecosystem for managing complex, global studies. Plus, every study is supported by a dedicated team of in-house clinical science and operations experts.

At Signant, our focus is helping you develop and deliver treatments or therapies faster in order to improve the quality of life for people living with GVHD

SIGNANT'S GVHD CLINICAL TRIAL EXPERIENCE

Phases

I II III

44
Languages

200+
Sites

30
Countries

500+
Patients

10
Protocols

SMARTSIGNALS SOLUTIONS

The SmartSignals solutions can be used individually or integrated together for a seamless, end-to-end digital experience.

eCOA

RTSM

eConsent

Scientific Advisory

Telemedicine

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



MEET THE EXPERTS